Glycostem presents virtually at Innate Killer Summit 2020 our production system for off-the-Shelf, GMP Compliant, fully closed & semi-automated large-scale (oNKord®) from fresh umbilical cord blood stem cells.
Glycostem is honored being seleced to be part of SVB Leerink Biopharma Private Company Connect on 7th to 9th July. It is a series of 1:1 between investors and Glycostem, one of the last formally organized investor conferences before the European summer break.
Glycostem CEO Troels Jordansen presents on 25th June at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.
Glycostem is invited to the second largest investor conference: the Jefferies Virtual Healthcare Conference on 4th July. The interest in off-the-shelf NK-cells with no CRS issues is increasing rapidly.
Glycostem presents at ACCESS CHINA Online Partnering Day on 15th May, 2020. ACCESS CHINA Partnering Day is the largest online corporate access event between China and Western Biopharma Industry. Glycostem is looking for investors and partnering opportunities.
On 14th May Glycostem presents virtually a poster at ASGCT 2020 about oNKord® “off-the-shelf” NK therapy closed system manufacturing process and clinical potential in AML, with a perspective on CAR-NK and other NK innovative therapies.